Trial intelligence / Profile preview

Cetuximab added to oxaliplatin, capecitabine, and preoperative radiotherapy for MRI-defined high-risk rectal cancer

2004-004707-38Phase 2Completed

Sponsor: Royal Marsden NHS Foundation Trust
Start: Feb 2005
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised, open-label trial of cetuximab in rectal adenocarcinoma and rectal cancer (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Complete response after neoadjuvant chemoradiotherapy and/or surgery in KRAS/BRAF wild-type tumors. Started Feb 2005; status: completed.

Drugs

cetuximab

Conditions

rectal adenocarcinomarectal cancer

Beyond the preview

Go deeper on 2004-004707-38.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-004707-38.